Between Dec 19, 2024 and Jan 2, 2025, datasets can be submitted to DRUM but will not be processed until after the break. Staff will not be available to answer email during this period, and will not be able to provide DOIs until after Jan 2. If you are in need of a DOI during this period, consider Dryad or OpenICPSR. Submission responses to the UDC may also be delayed during this time.
 

Characterization of Death Receptor 5 Targeting Nanoring Cancer Drugs

Palmatier, Katelyn
2012-04-18
Thumbnail Image

View/Download File

Palmatier_UROP.pdf (579.62 KB)

Persistent link to this item

https://hdl.handle.net/11299/133312
Statistics
View Statistics

Journal Title

Journal ISSN

Volume Title

Title

Characterization of Death Receptor 5 Targeting Nanoring Cancer Drugs

Authors

Published Date

2012-04-18

Publisher

Type

Presentation

Abstract

To maximize the effectiveness and minimize the adverse effects of chemotherapeutic agents, it is strategic to create drugs that specifically target cancer cells via ligand-receptor interactions. Several variations of a drug containing a ligand that binds to Death Receptor 5 were created and in vitro properties were characterized.

Keywords

Description

Faculty Advisor: Dr. Carston R. Wagner

Related to

Replaces

License

Collections

UMTC Undergraduate Research Presentations and Papers (UROP)

Series/Report Number

Funding information

This research was supported by the Undergraduate Research Opportunities Program (UROP).

Isbn identifier

Doi identifier

Previously Published Citation

Other identifiers

Suggested citation

Palmatier, Katelyn. (2012). Characterization of Death Receptor 5 Targeting Nanoring Cancer Drugs. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/133312.

Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.